

Press release October 18, 2021

The clinic of Oncology at the University Hospital in Linköping buys VibroSense Meter® II and starts a multicentre study

The Department of Oncology at Linköping University Hospital has started a multicentre study to identify biomarkers for advanced pancreatic cancer that are treated with chemotherapy. The study will be made in collaboration with VibroSense Dynamics which assists with advice and data extraction as well as analysis of data. The studies aim to investigate how nerves in the feet and hands are affected by chemotherapy.

The study will be conducted at three clinics in the Swedish hospitals in Linköping, Jönköping and Kalmar of initially 75 patients during two years. The purpose of the study is to identify and explore biomarkers for predicting outcomes and negative effects in connection with chemotherapy treatment in order to find future biomarkers for individualized treatment decisions.

This includes investigating the possibility of early detection of chemotherapy induced nerve damage with the VibroSense Meter® II instrument.

- Treatment of cancer with chemotherapy is of utmost importance for the good care of the patients, but usually has a small therapeutic window. Hence, there is a small difference between doses that result in a therapeutic effect and doses that result in toxicity. Finding better tools for individualized treatment is therefore extremely important. We want to identify new Biomarkers to optimize the treatment of patients with advanced pancreatic cancer. We look forward to investigating Multi Frequency Vibrometry and the potential of the method to improve treatment and monitor the development of nerve damage for a more individualized care, says Henrik Green professor at Linköping University Hospital (LIU).
- I am very pleased with the collaboration now started with Professor Henrik Green and Linköping University Hospital. The research area is very interesting and we hope that the study will provide continued support and evidence that our instrument can be used to predict the outcome of nerve damage even before starting anti-cancer treatment, says Hans Wallin, CEO of VibroSense Dynamics AB.

Contact

Hans Wallin, CEO VibroSense Dynamics AB,

Phone: +46 40 88 026

E-mail: info@vibrosense.com

www.vibrosense.com

About cancer treatment with Chemotherapy

It is well known that chemotherapy is generally associated with significant individual variation in therapeutic effect and side effects in the form of nerve damage. Drug doses are routinely adjusted according to body surface area, which is a simple but unfortunately very rough tool for determining the right doses.

Many reports show that the therapeutic effects and severe nerve damage at a given dose can vary considerably between patients with the same bodily functions, the same diagnosis, histology and stage of the disease.

According to the latest edition of the World Cancer Report 2020, over 19 million new cancer diagnoses are made per year, of which approximately 2.26 million (11.7%) are breast cancer, 2.20 million (11.4%) lung cancer and 1.9 million (10%) colorectal cancer. In the United States alone, the care of cancer patients costs just over \$ 208 billion per year.

About VibroSense Dynamics AB (publ)

VibroSense Dynamics AB (public) sells and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.